Edwin E. Jeng

1.8k total citations · 1 hit paper
17 papers, 973 citations indexed

About

Edwin E. Jeng is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Edwin E. Jeng has authored 17 papers receiving a total of 973 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 7 papers in Oncology and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Edwin E. Jeng's work include Chronic Lymphocytic Leukemia Research (3 papers), Lung Cancer Research Studies (3 papers) and Lung Cancer Treatments and Mutations (3 papers). Edwin E. Jeng is often cited by papers focused on Chronic Lymphocytic Leukemia Research (3 papers), Lung Cancer Research Studies (3 papers) and Lung Cancer Treatments and Mutations (3 papers). Edwin E. Jeng collaborates with scholars based in United States, Spain and South Korea. Edwin E. Jeng's co-authors include Michael C. Bassik, Kyuho Han, David W. Morgens, Amy Li, Gaelen T. Hess, M Snyder, Ryan Raisner, Steven Magnuson, Mark Merchant and Tommy K. Cheung and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Blood.

In The Last Decade

Edwin E. Jeng

16 papers receiving 964 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Synergistic drug combinations for cancer identified in a CRISPR screen for pairwise genetic interactions

2017 368 citations Kyuho Han, Edwin E. Jeng et al. Nature Biotechnology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Edwin E. Jeng United States	8	793	133	88	83	81	17	973
Christopher J. Giuliano United States	8	662 0.8×	144 1.1×	82 0.9×	67 0.8×	81 1.0×	12	920
Jani Saarela Finland	19	583 0.7×	163 1.2×	151 1.7×	80 1.0×	97 1.2×	45	999
Emanuel Gonçalves United Kingdom	17	757 1.0×	131 1.0×	84 1.0×	87 1.0×	179 2.2×	31	940
Almer M. van der Sloot Spain	20	848 1.1×	186 1.4×	47 0.5×	61 0.7×	94 1.2×	36	1.1k
Jon Travers United Kingdom	9	501 0.6×	270 2.0×	63 0.7×	42 0.5×	80 1.0×	23	659
Patricia Mero Canada	8	978 1.2×	175 1.3×	30 0.3×	124 1.5×	125 1.5×	14	1.2k
Engin Cukuroglu Singapore	14	695 0.9×	174 1.3×	134 1.5×	50 0.6×	102 1.3×	18	959
Nicodème Paul France	17	628 0.8×	118 0.9×	158 1.8×	65 0.8×	213 2.6×	30	953
Luz García‐Alonso United Kingdom	15	1.1k 1.4×	156 1.2×	96 1.1×	161 1.9×	215 2.7×	23	1.5k
Celia Fontanillo Spain	16	835 1.1×	136 1.0×	154 1.8×	81 1.0×	229 2.8×	27	1.2k

Countries citing papers authored by Edwin E. Jeng

Since Specialization

Citations

This map shows the geographic impact of Edwin E. Jeng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edwin E. Jeng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edwin E. Jeng more than expected).

Fields of papers citing papers by Edwin E. Jeng

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Edwin E. Jeng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edwin E. Jeng. The network helps show where Edwin E. Jeng may publish in the future.

Co-authorship network of co-authors of Edwin E. Jeng

This figure shows the co-authorship network connecting the top 25 collaborators of Edwin E. Jeng. A scholar is included among the top collaborators of Edwin E. Jeng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Edwin E. Jeng. Edwin E. Jeng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Gurion, Ronit, Catherine Thiéblemont, Won Seog Kim, et al.. (2024). Fixed-Duration Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results from Arm 1 of the Epcore NHL-5 Trial. Blood. 144(Supplement 1). 3110–3110. 7 indexed citations

Özcan, Muhıt, Maria Bouzani, Zsolt Nagy, et al.. (2024). Phase 3, Randomized, Open-Label Study of Epcoritamab Plus Lenalidomide Compared with Rituximab Plus Gemcitabine and Oxaliplatin in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Blood. 144(Supplement 1). 4502.1–4502.1. 2 indexed citations

Cho, Byoung Chul, Melissa L. Johnson, Jair Bar, et al.. (2023). 655O Phase Ib study of cofetuzumab pelidotin, an anti-PTK7 antibody-drug conjugate, in patients with PTK7-expressing recurrent non-small cell lung cancer (rNSCLC). Annals of Oncology. 34. S460–S461. 5 indexed citations

Chandana, Sreenivasa R, Benjamin Garmezy, Afshin Dowlati, et al.. (2023). 2029TiP Phase I study of ABBV-706, an anti-SEZ6 antibody-drug conjugate, alone or in combination in adults with advanced solid tumors. Annals of Oncology. 34. S1077–S1077. 3 indexed citations

Ansell, Peter, D. Ross Camidge, Shobhit Baijal, et al.. (2023). Evaluation of the prevalence of MET and protein tyrosine kinase 7 expression in non-small cell lung cancer to evaluate overlap of ADC antigens.. Journal of Clinical Oncology. 41(16_suppl). e21105–e21105. 1 indexed citations

Morgensztern, Daniel, Neal Ready, Melissa L. Johnson, et al.. (2023). First-in-human study of ABBV-011, a seizure-related homolog protein 6 (SEZ6)–targeting antibody-drug conjugate, in patients with small cell lung cancer.. Journal of Clinical Oncology. 41(16_suppl). 3002–3002. 15 indexed citations

Xu, Qingqing, et al.. (2023). EP13.06-03 Real-World Outcomes in Patients with 3rd-Line Extensive Stage Small Cell Lung Cancer. Journal of Thoracic Oncology. 18(11). S704–S704. 1 indexed citations

Kim, Won Seog, Po‐Shen Ko, Carlos Grande, et al.. (2023). Subcutaneous Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma from EPCORE NHL-5. Blood. 142(Supplement 1). 438–438. 13 indexed citations

Cohen, Allison, et al.. (2022). Genome-scale CRISPR screening reveals that C3aR signaling is critical for rapid capture of fungi by macrophages. PLoS Pathogens. 18(9). e1010237–e1010237. 7 indexed citations

10.

Schaefer, Eric, D. Ross Camidge, Kiyotaka Yoh, et al.. (2021). A phase 1b, open-label, single-arm study of cofetuzumab pelidotin (a PTK7-targeting antibody-drug conjugate) in patients with PTK7-expressing, recurrent non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 39(15_suppl). TPS3142–TPS3142. 5 indexed citations

11.

Kelly, Marcus R., Kaja Kostyrko, Kyuho Han, et al.. (2020). Combined Proteomic and Genetic Interaction Mapping Reveals New RAS Effector Pathways and Susceptibilities. Cancer Discovery. 10(12). 1950–1967. 30 indexed citations

12.

Jeng, Edwin E., Lihua Jiang, Joanne Chan, et al.. (2019). Systematic Identification of Host Cell Regulators of Legionella pneumophila Pathogenesis Using a Genome-wide CRISPR Screen. Cell Host & Microbe. 26(4). 551–563.e6. 69 indexed citations

13.

Duque‐Afonso, Jesús, Kyuho Han, David W. Morgens, et al.. (2018). CBP Modulates Sensitivity to Dasatinib in Pre-BCR+ Acute Lymphoblastic Leukemia. Cancer Research. 78(22). 6497–6508. 12 indexed citations

14.

Raisner, Ryan, Samir Kharbanda, Lingyan Jin, et al.. (2018). Enhancer Activity Requires CBP/P300 Bromodomain-Dependent Histone H3K27 Acetylation. Cell Reports. 24(7). 1722–1729. 223 indexed citations

15.

Kostyrko, Kaja, Kyuho Han, Marcus R. Kelly, et al.. (2018). SPOT-007 Identifying novel combinatorial synthetic lethal vulnerabilities in KRAS-driven lung cancer. ESMO Open. 3. A18–A18. 1 indexed citations

16.

Morgens, David W., Michael Wainberg, Evan A. Boyle, et al.. (2017). Genome-scale measurement of off-target activity using Cas9 toxicity in high-throughput screens. Nature Communications. 8(1). 15178–15178. 211 indexed citations

17.

Han, Kyuho, Edwin E. Jeng, Gaelen T. Hess, et al.. (2017). Synergistic drug combinations for cancer identified in a CRISPR screen for pairwise genetic interactions. Nature Biotechnology. 35(5). 463–474. 368 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact